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Immunomodulation of peritoneal macrophages by granulocyte-mac-
rophage colony-stimulating factor in humans. Colony-stimulating factors
are growth factors which induce differentiation of the hematopoietic stem
cells. Granulocyte-macrophage colony-stimulating factor (GM-CSF) stim-
ulates proliferation and improves functions of neutrophils and monocyte/
macrophages. A macrophage submesothelial stratum has been suggested
to constitute the first line of peritoneal defense. We have tested whether
intraperitoneally administered GM-CSF could increase the number and
activation of peritoneal macrophages in peritoneal dialysis patients. Eight
stable patients injected 17 j.rg of GM-CSF in each of their four daily
CAPD bags over three days. The clinical status, the peritoneal effluent and
peripheral blood cell count, membrane receptor expression, phagocytosis
activity and eytokine levels were monitored at days 0, 1, 3, 10 and 28.
GM-CSF administration caused a large increase in peritoneal macrophage
number (89-fold mean increase after 72 hr), returning to baseline seven
days after withdrawal. GM-CSF triggered an increase in the expression of
CDI1b/CD18 (CR3) and its counterreceptor CD54, indicating the cellular
progression into a more activated state. Both the number of phagocytic
cells (55 15% to 83 10%, P < 0.05) and the phagocytic index (137
29 to 255 61, P < 0.01) were also augmented. Peritoneal effluent
cytokine-chemokine levels demonstrated an increase in IL-6 and MCP-1
levels, while TNF-a, IL-i, IL-8, MIP-la and RANTES were not signifi-
cantly altered. GM-CSF administration did not affect the peritoneal
transport of water or solutes. Minor side-effects were registered in two
patients. In conclusion, intraperitoneal GM-CSF causes a marked and
transient recruitment of primed macrophages into the peritoneum without
inducing inflammatory parameters. GM-CSF should improve the perito-
neal defensive capacity through potentiation of the effeetor functions of
resident and newly-recruited macrophages.
The peritoneal membrane is subjected to adverse conditions in
peritoneal dialysis (PD). The peritoneum of PD patients exhibits
lower than normal immune responses [I] and infections are
frequently found in continuous ambulatory peritoneal dialysis
patients [2]. It has been suggested that a macrophage submesothe-
hal stratum constitutes the first line of immune defense of the
peritoneum [3]. Prolonged PD treatment lowers the number of
floating macrophages in peritoneal effluent, suggesting that the
ability of the peritoneum to mount an inflammatory response
might be impaired by the daily lavage [4, 5]. Four-20 X 106
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peritoneal macrophages eliminated daily [6] may explain their
immature phenotype in CAPD patients [7—111. Currently used
dialysate impairs most peritoneal macrophage effeetor functions
[12, 13], reducing secretion of IL-1f3 [14, 15], thus emphasizing a
defective capacity of the peritoneum of CAPD patients [16].
Colony-stimulating factors (CSF) are natural growth factors
able to induce either self-renewal or differentiation of the pluri-
potent hematopoictic stem cells. GM-CSF acts on neutrophils and
monocyte/macrophages precursors by stimulating their prolifera-
tion and differentiation in bone marrow [17—19] and improving
their effector functions [20, 21].
Since a minimum number of macrophages appears to be
required to eliminate the amounts of bacteria that may contami-
nate peritoneal dialysis solutions [12], and given that peritoneal
defense mechanisms suffice to clear invading bacteria below a
certain contamination threshold [16], an increase in macrophage
number and cytotoxic capacity might be sufficient to eliminate the
small number of microbes that a CAPD patient might receive.
Given the stimulatory properties of GM-CSF [17, 22—24] and its
ability to induce macrophage recruitment in mouse peritoneum
[25], we hypothesized that GM-CSF might he administered intra-
peritoneally to CAPD patients to increase both the number and
functional maturity of peritoneal macrophages, improving the first
line of peritoneal defense against infections.
Methods
Patients
Eight stable patients (25 to 70 years old) on CAPD for one to
three years, seven female, were selected among those willing to
cooperate and understand the objectives, after reading and sign-
ing an informed consent. The Ethical Committee of our Institu-
tion approved the trial. The underlying renal diseases were
diabetic ncphropathy (3 patients), chronic glomerulonephritis
(three) and interstitial nephropathy (2). Previous peritonitis inci-
dence was 0 to 2.4 episodes/year. Abnormal peritoneal situations
were excluded by peritoneal functional data, nocturnal peritoneal
effluent (NPE) cell populations and bacterial culture. The clinical
status of each patient was monitored by blood cell count and daily
NPE cellularity at days 0, 1 and 3 during the treatment, and one
and four weeks after GM-CSF withdrawal. Patients were taught to
inject 17 j.g of GM-CSF (Schering-Plough) in each of their four
daily CAPD bags over three consecutive days. The dose was
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Table 1. Monoclonal antibodies used in this study
CD group Clone Specificity Marker Supplier
CD11a 25.3 a chain of LFA-1 FTTC Immunotech
CDIIb D12 a chain of MAC-I PE Becton-Dickinson
CDI1c HC1/1 a chain of p150,95 FITC Dr. C. Bernabeu
CD18 TSIII8 j3 chain of LeuCAMs FITC Dr. T. Springer
CD14 MfP9 LPS-LPB Re PE Becton-Dickinson
CDI6 NKP15 FC-T-RIIJ FITC Becton-Dickinson
CD64 32.2 Fc-T-RI PE Caltag
CD54 LB2 ICAM-1 PE Becton-Dickinson
CD71
—
4DJ1.2.2
L243
Transferrin Re
HLA-DR
FITC
PE
Immunotech
Becton-Dickinson
chosen according to the lowest doses proposed (0.3 to 10 igIkgI
day) [22]. The same time schedule and dialysate (glucose 2.5%, Ca
1.75 mmol/liter) were used.
The following determinations were carried out.
Cells. Peritoneal cells were isolated from the NPE after an
overnight dwell time [4]. The complete volume collected was
centrifuged (450 g for 10 mm) and the supernatants kept at —70°C
for cytokine level determination. Cells were pooled and resus-
pended either in PBS for morphological studies, in autologous
plasma for the phagocytosis test or in PBSIAB for flow cytometry
(1 to 2 >< 10°/mI final cell concentration). For cell counts and
receptor determinations, PB cells were collected in EDTA-K3
anticoagulant-containing tubes. For phagocytic activity, hepa-
rinjzed blood (4 IU/ml) was used. Cells were counted in a
Neubauer chamber. Whole blood PB cells were measured using a
Technicon H2 system (Bayer Diagnostics). For differential cell
counts, cell suspensions were cytocentrifuged and stained with
Wright's solution. Cell viability was determined by trypan blue
exclusion.
Immunofluorescence and flow cytometly. Cell immunophenotype
was studied using direct and indirect immunofluorescence tech-
niques [26, 27] for both techniques; murine anti-human monoclo-
nal antibodies were used (Table 1) and a second FITC-labed
F(ab')2 goat anti-mouse antibody was added in the indirect
technique. All incubations were done in the presence of 2%
human AB serum. Negative controls using irrelevant antibodies
were used simultaneously. Cells were finally resuspended in 500 p.l
of 1% paraformaldehyde in PBS and stored at 4°C until analysis.
Flow cytometry was performed using a FACScanR system (Bee-
ton-Dickinson). Results obtained were expressed as the percent-
age of positive fluorescent cells and as lineal-scale transformed
mean fluorescence intensity (MFI).
Cytokine detenninations. IL-1/3, IL-6, IL-8, TNF-cs, MIP-la
(macrophage inflammatory protein-i a), RANTES (regulated
upon activation, normal T-cell expressed and presumably se-
creted) and MCP-1 (monocyte chemoattractant protein-i) con-
centrations were calculated in a solid-phase ELISA (R&D Sys-
tems) on days 0, 3 and 10 of the treatment schedule. A best-fit
calibration curve for each cytokine was drawn by plotting the
optical density for the standards versus their respective concen-
trations. Control measurements were done using the manufactur-
er's supplied controls, previously diluted in the peritoneal dialysis
solution. (1) The respective intra-assay precision was lower than
the following: IL-i, 9%; TNF-a, 5%; IL-6, 4.5%; IL-8, 4%;
MIP-ia, 9%; RANTES, 4.5; MCP-1, 4.5%. (2) The respective
interassay precision was lower than: IL-I, 9%; TNF-a, 7.5%; IL-6,
6.5%; IL-8, 10%; MIP-la, 4%; RANTES, 6; MCP-1, 6%. (3) The
respective minimum detectable values were (pglml): IL-i, 0.3;
TNF-a, 4.4; IL-6, 0.7; IL-8, 3; MIP-la, 3; RANTES: 5; MCP-1: 5.
Phagocytic assays. Phagocytic activity was evaluated using a
commercially available kit (PhagotestR; Orpegen Pharma) on
days 0, 3 and 10 of the treatment schedule. This test uses a
stabilized and opsonized FITC-labeled E. coli suspension. The
method was as follows: 100 l of a cell suspension from NPE or
peripheral blood were incubated in ice, then 20 1.d of E. coli
suspension (1 X 10°Iml) were added. The negative controls
remained in ice while assay samples were incubated for 10
minutes. at 37°C. Afterwards, all samples were put into ice to stop
phagocytosis and 100 jil of quenching solution were added to each
sample. All tubes were washed twice and spun (250 g at 4°C, for
5 mm). After erythrocyte lysis, 100 id of DNA staining solution
were added and the samples were incubated for 10 minutes in ice
and protected from light. The phagocytosis was measured in a
flow cytometer (FACScan' System; Becton-Dickinson) within 30
minutes. Only the cells with stained DNA were acquitted using
proper gates. Macrophages and neutrophils that phagocytized
were analyzed according to their forward and side scatters. The
intraassay precision was lower than 5%.
Other determinations
The CA-125 antigen level was measured in NPE [28] by
radioimmunoassay (cA-i25 IITMK, P2002; Sorin Biomedica).
NPE protein losses were monitored using the Bradford method.
Peritoneal ultrafiltration capacity was sequentially measured by
net fluid balance. A solute (urea, creatinine, phosphorus, sodium,
potassium and calcium) peritoneal kinetic study (D/P ratio and
mass transfer coefficient (MTC) calculation) was performed dur-
ing the first CAPD exchange with GM-CSF administration. A
clinical survey and physical examination were done at time 0 and
after 1, 3, 7 and 24 days of GM-CSF treatment.
Statistical analyses
Data are described as mean SD. Differences among data were
assessed using non-parametric Wilcoxon's (days 0 and 3) and
Friedman's (days 0, 3 and 10) tests. Correlation among data were
carried out with the Spearman and Pearson correlation indexes.
Results
GM-CSF induces monocyte/macrophage recruitment into the
peritoneum
NPE collected cells were predominantly macrophages and
lymphocytes (range 0.048 to 5.74 X 106 and 0.07 to 3.15 x 106,
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Fig. 1. Changes in NPE cells population during and after GM-CSF intraperitoneal administration measured in million cells per night. Symbols are: (Y)
patient 1; (+) patient 2; () patient 3; (•) patient 4; (*) patient 5; (•) patient 6; (A) patient 7; () patient 8.
respectively), with other cell populations exhibiting remarkable
lower values (Fig. 1). After GM-CSF administration, the eight
patients showed a 19-fold mean increase in peritoneal macro-
phage count after 24 hours (1.5 1.8 to 29 45 X 106 cells/night,
P < 0.05) and 88-fold after 72 hours (132 223 X 106 cells/night,
P < 0.05). Neutrophil count also showed a variable increase, with
major increments in three patients with the highest macrophage
recruitment. Lymphocyte count also increased significantly after
72 hours, although to a much lower extent than macrophages or
neutrophils. Finally, eosinophils and basophils show significant
increments after GM-CSF treatment, with increments up to
100-fold in some cases. As a whole, NPE cell counts were greatly
increased in all patients, although responses differed both in
intensity and kinetics, and baseline values were always restored
seven days after withdrawal of GM-CSF. As shown in Table 2, the
relative peritoneal macrophage increment after three days did not
show significant correlation with the increment of peritoneal
neutrophils (r = 0.6). Conversely, peritoneal lymphocyte incre-
ment correlated with both macrophage and neutrophil increments
(r = 0.7 and 0.82, respectively; P < 0.05), as well as with
mesothelial cell (r = 0.92) and eosinophil (r = 0.76) increases.
Macrophage viability tests after 72 hours showed a significant
improvement (91 vs. 99%). Unlike cells collected during perito-
nitis episodes, the morphological appearance of GM-CSF-re-
cruited macrophages and neutrophils was compatible with that of
non-inflammatory cells, as indicated by the absence of homotypic
aggregation and their much higher content of intracellular gran-
ules.
Table 2. Relative increments of peritoneal cells after three days of i.p.
GM-CSF administration
Mesothelial
Patient Macrophages Neutrophils cells
#1 37.4 481.5 0.003
#2 231.6 14438.5 200.5
#3 697.5 6903.0 23.5
#4 5.0 2.8 1.0
#5 377.0 12067.8 553.6
#6 7.7 105.9 1
#7 8.7 3.4 12.6
#8 95.2 25.5 2.0
In contrast to blood-borne cells, NPE mesothelial cells in-
creased only in the two patients exhibiting the highest neutrophil
recruitment (Fig. 1), although their morphology did not show cell
damage-associated macroscopic abnormalities (data not shown).
Peripheral blood monocyte, lymphocyte, neutrophil and eosino-
phil counts showed only a slight increase (1.5- to 2.5-fold) after
the 72 hour GM-CSF treatment. Peripheral blood monocyte
count was elevated from 0.44 0.04 to 0.7 0.11 X 106/mm3
after 24 hours and to 0.68 0.07 X 106/mm3 after 72 hours (data
not shown). Interestingly, although peripheral blood cell levels
had returned to baseline values seven days after withdrawal of the
GM-CSF treatment, peripheral blood lymphocytes remained
slightly elevated (data not shown).
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Table 3. Peritoneal macrophage CD expression (mean values SD) after three days of GM-CSF treatment
Day 0 Day 3 Day 10
% MFI % MFI % MFI
CD 14 63.5 18.4 152.6 43.1 87.5 12.3 149.3 55.2 63.3 21.8 175.5 69.9
CD 54 94.6 5.5 81.1 24.9 98.5 2W' 175.0 55.2a 92.0 7.5 108.1 493
CD ha 94.0 4.0 57.7 18.9 98.7 1.7 62.2 11.2 94.7 4.5 53.9 15.1
CD lib 91.4 4.7 151.5 32.1 97.7 IT 394.7 108.Oa 87.8 7.4 155.6 32.7
CD 18 90.4 14 42.9 24.1 99.7 0.7 75.7 46 94.66 9.7 41.8 22.2
CD 16 84.7 30.7 18.1 9 88.7 25 14.0 4.8 94.6 5.6 25.1 12.3
HLA DR 95.4 4.9 907.9 99.7 98.8 2.2a 860.4 128.4 97.2 2.5 917.4 124.1
CD 71 77.5 41.6 10.2 4.1 95.9 8.4 13.2 3.6 93.8 10.3 10.9 3.2
%: Percentage of positive cells. MFI: Mean fluorescence intensity
a P < 0.05
Fig. 2. Phagocytic capacity of peritoneal
macrophages and peripheral blood monocytes
before and after intraperitoneal GM-CSF
administration, measured as the percentage of
phagocytic cells (A) or as phagocytic intensity (B)
after three days of GM-CSF treatment. Results
shown are the mean of eight determinations.
Symbols are: () day 0; () day 3; (D) day 10.
Immunophenolype and activation state of the recruited
macrophage population and peripheral blood monocytes
To evaluate the effector capabilities of the GM-CSF-recruited
cells, the expression of cell activation-associated surface mole-
cules was determined. As shown in Table 3, a marked and
significant increase in the CD1 lb/CDI8 integrin heterodimer was
observed in the GM-CSF-recruited peritoneal macrophages,
which must reflect the release of CDIIb/CD 18-containing tertiary
granules from monocytes during their migration into the perito-
neal cavity. Simultaneously, the expression of the CDIIa/CD18-
and CDI1b!CD18-counterreceptor CD54 (ICAM-1) was also
elevated in peritoneal macrophages (Table 3). The three-day
GM-CSF treatment elevated the number of CD54-positive pe-
ripheral blood monocytes (89.3 9 to 95.2 3.4%, P < 0.05), as
well as their expression of CDI lb (MFI 56 17 to 142 91, P <
0.05) and HLA-DR (MFI 217 48 vs. 318 122, P < 0.05; data
not shown). All these changes return to baseline values seven days
after GM-CSF withdrawal, These results strongly suggest that
macrophage activation had occurred.
To determine whether GM-CSF could potentiate peritoneal
macrophage phagocytic capacity, this parameter was measured
both in patient peritoneal macrophages and peripheral blood
monocytes during GM-CSF administration. A significant increase
in the peritoneal macrophage phagocytic capacity was observed,
measured both as the percentage of phagocytic cells (55 15% to
83 10%, P < 0.05) and the number of ingested microorganisms
(MFI 137 29 to 255 62, P < 0.01), further suggesting that
GM-CSF has induced a bona fide macrophage activation. How-
ever, no significant effect of the GM-CSF treatment on the
phagocytic capacity of peripheral blood monocytes was observed
[71 15 to 78 18 (%) and 218 80 to 287 134 (MFI); Fig.
2].
Cytokines and chemokines in nocturnal peritoneal effluent
Leukocytes are recruited into inflammatory sites through the
activity of chemoattractant molecules. To determine the involve-
ment of cytokines and chcmokines in the cell recruitment into
the peritoneum, we measured NPE IL-13, TNF-a, IL-6, IL-8,
RANTES, MIP-Ia and MCP-1 levels. Surprisingly, the only
significant increments were observed for IL-6 (from 76.25 67.08
to 2858.5 4258.7 pg/mI after 72 hr and 68.87 70.99 pg/mI
seven days after withdrawal, P < 0.05) and for MCP-1 (from
677 221 to 2457 1637 pg/mI after 72 hr, and 822 375 pg/mI
seven days after withdrawal, P < 0.05; Fig. 3 and Table 4). While
background levels were similar to those reported in stable pen-
toneum (15 to 170 pg/ml), IL-6 levels increased in a variable
manner in GM-CSF-treated patients (Table 4) and correlated
with the GM-CSF-dependent macrophage recruitment (r = 0.95,
P < 0.05). Also, NPE MCP-l levels correlated with the number of
macrophages recruited (r = 0.78, P < 0.05, at day 3). The
010,000
increment of this chemokine correlated significantly with that of
macrophages at day 3 as well (r = 0.9, P < 0.05).
On the other hand, other cytokines exhibited no significant
alterations, although IL-1f3 levels were elevated in the two
patients showing the highest NPE IL-6 increments. In any event,
the concentrations measured in the NPE from GM-CSF-treated
patients were well below the known effective concentration of
each individual factor under inflammatory conditions. Table 4
summarizes the individual relative changes of peritoneal cytokine
levels.
Table 4. Individual relative cytokine increments after three days of i.p.
GM-CSF administration
Patient IL-1f3 TNF-a IL-6 IL-8 RANTES MIP-ics MCP-1
#1 1.3 1.1 22.5 3.0 1.0 0.9 2.9
#2 1.2 1.0 22.7 1.2 1.0 1.0 5.4
#3 3.4 1.3 333.3 17.3 1.0 1.5 8.0
#4 1.4 1.1 0.5 1.1 1.0 1.0 2.1
#5 6.2 0.9 182.0 0.8 1.0 1.5 7.5
#6 0.9 0.9 1.7 1.2 1.0 1.0 1.5
#7 0.4 1.0 10.4 23.4 0.9 1.2 2.6
#8 1.0 1.0 5.47 3.7 1.0 1.0 1.1
Effect of GM-CSF on peritoneal functional parameters
To determine the putative detrimental effect that recruited cells
might have on the peritoneum, we evaluated peritoneal transport
of water and solutes. Water transport showed no significant
changes (1200 672 ml/24 hr at baseline, 1050 652 on day 3
and 1328 398 at day 10). Similarly, transport of urea, creatinine,
potassium, phosphorus and bicarbonate, evaluated both during
the first GM-CSF dose and after one month of GM-CSF with-
drawal, did not significantly differ from previous values of these
patients (MTC values 20.3 10.1, 11.4 4.7, 17.5 7.8, 7.07
3.0 and 16.9 7.1 mI/mm, respectively). Peritoneal protein losses
showed a slight increase after three days (1.6 0.6 to 2 0.6 gIl;
data not shown).
The eight patients showed a statistically non-significant incre-
ment of CA-125 at 72 hours (15.2 7.1 vs. 22.6 13.2 lU/mI; Fig.
4). Although individual CA-125 NPE values increased 1.8 to 4.3
times in the three patients with the highest NPE cell count
increments, NPE CA-125 levels were unaffected in the remainder.
These results suggest the lack of mesothelial cell injury, in
agreement with the morphological studies.
Clinical effects of GM-CSF
Only two patients, who presented the most intense cell recruit-
ment, complained of a transitory flu-like syndrome during the
third day. Patients' weight, blood pressure and biochemical data
showed no significant changes during the study.
Discussion
Improvement of the peritoneum capacity to mediate effective
defensive responses is a requirement in CAPD patients. In this
report we describe that intraperitoneally administered GM-CSF
causes a marked, transient recruitment of macrophages into the
peritoneum, with variable intensity and kinetics. Based on NPE
cytokine levels and the cell morphology, these alterations do not
appear to be due to an inflammatory phenomenon. Instead, the
macrophage immunophenotype and the improvement in the
phagocytic capacity [30] are in accordance with the induction of
elicited or primed macrophages recruited into the peritoneum
through a GM-CSF-triggered chemotactic gradient. In fact, since
GM-CSF is most chemokinetic on neutrophils [31], the macro-
phage recruitment might be mediated by a direct effect of
GM-CSF on macrophage motility and, secondarily, by chemoat-
tractant molecules released in response to the i.p. administered
GM-CSF.
Intraperitoneal GM-CSF administration leads to a notable
NPE macrophage recruitment, with increments of nearly 700-fold.
To the best of our knowledge, this is the first report on the effects
of i.p. administered GM-CSF in humans. Our data support the
hypothesis that GM-CSF induces a recruitment of primed mac-
rophages [3]. These results are in agreement with the dose-
dependent increase in the total number and effector functions of
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Fig. 3. Individual NPE MCP-1 levels during and
after intraperitoneal GM-CSF administration.10 Symbols are: (V) patient 1; (+) patient 2; (1i)
patient 3; () patient 4; (*) patient 5; (+)
patient 6; (A) patient 7; x) patient 8.
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Fig. 4. Individual NPE CA -1 25 levels during and2 3 4 5 6 7 8 after intraperitoneal GM-CSF administration.
Symbols are: () day 0; () day6 3; (Q) dayPatient number 10.
macrophages, eosinophils and neutrophils previously described
upon i.p. GM-CSF administration in mice [25]. However, unlike
Metcalf and coworkers [25], we detected no mitosis in the
GM-CSF-recruited macrophage population. Our results also
agree with studies on GM-CSF transgenic mice, in which pleural
and peritoneal macrophages were found increased in number and
in functional capabilities [32].
GM-CSF promotes a number of macrophage and granulocyte
effector functions, including cell survival [20, 33—36], production
of oxygen active metabolites [20, 32, 37—39], TNFa and antibody-
mediated cytotoxicity [20, 34, 40, 41], phagocytosis and intracel-
lular killing of microorganisms [20, 34, 38, 39], inhibition of
intracellular growth of parasites [42, 43], and TNFs and IL-i
secretion in combination with LPS, all of which contribute to the
elimination of infectious organisms. Our results reveal that GM-
CSF enhances the phagocytic capacity of peritoneal macrophages
in all patients treated, not only by increasing the number of
phagocytes, but also the number of E. coli ingested per cell.
Peritoneal macrophages from apparently non-infected CAPD
patients have phagocytic capacity [44], although it is generally
assumed that the peritoneum exhibits an insufficient number of
phagocytes [30]. The massive GM-CSF-mediated macrophage
migration into the peritoneum could overcome this deficiency.
According to the estimates of Verbrugh et a! [12], a sufficient
number of macrophages would be recruited to allow for efficient
elimination of the expected amount of contaminating bacteria in
the peritoneum of CAPD patients.
GM-CSF increases cell surface expression of the CD11b/CD18
and CD1 Ic/CD 1 8 integrins on monocytes, neutrophils and eosin-
ophils, thus improving their adhesion to endothelial cells and
plastic surfaces [20, 45—49]. In fact, in vivo GM-CSF administra-
tion produces a rapid and transient reduction in circulating
neutrophils [50, 51]. The up-regulated expression of CD1 lb on
peripheral blood monocytes from GM-CSF-treated patients
clearly indicates that GM-CSF has activated circulating mono-
cytes, leading to the release of CD1 lb/CD 1 ic integrin-containing
granules. This activation may also trigger the acquisition of the
high affinity state for the integrin ligands needed for transendo-
thelial migration (LFA-l, Mac-i, p150,95, VLA-4) [52]. Given the
expression of the integrin counter-receptors CD54 (ICAM-1) and
CD1O6 (VCAM-l) on cultured mesothelial cells [3, 53, 54], it is
tempting to speculate that monocytes, after passing through the
endothelial layer, accumulate in a submesothelial stratum. Upon
continuous administration of GM-CSF in the peritoneum, such a
macrophage submesothelial layer would further migrate into the
peritoneal cavity, remaining loosely adherent to the mesothelial
layer and being washed off the cells during the lavage process
caused by the dialysate exchange. The increased expression of
CD54 would reflect the activation of the newly-recruited macro-
phage population during the trans-endothelial and trans-mesothe-
hal passage, especially since CD54 expression is dependent on the
nuclear factor-KB (NF-KB) transcription factor, whose activity is
inhibited by the dialysis solution [55] (see below). We have
examined NPE level changes of three C-C-chemokines
(RANTES, MIP-la and MCP-l) able to recruit monocytes into
tissues. MCP-1 was the only which significantly changed (mean
increment 3.6-fold at day 3). It has been described that this
chemokine increases 60-fold in peritoneal inflammatoiy states
[56]. None of our patients reached such a change. Both mesothe-
hal cells [53] and macrophages [56] are able to release MCP-i in
response to different stimuli. GM-CSF induces the secretion of
chemokines by macrophages, but we have no data on the effects of
GM-CSF in MCP-1 releasing in particular. Our data might be
expressive that this situation occurs in peritoneal macrophages. In
consequence, the recruitment of macrophages into the perito-
neum induced by GM-CSF, might be the result of a direct
chemokine effect by GM-CSF, an indirect effect mediated by
MCP-i or both stimuli acting simultaneously.
GM-CSF administration also led to a neutrophil recruitment
into the peritoneum in all patients, in agreement with the data
reported in the murine model [25]. However, the neutrophil
migration into the peritoneum was extremely variable among
patients and did not correlate with the peritoneal macrophage
increase. This phenomenon could be explained in part by the
inhibitory effect of GM-CSF on neutrophil transendothelial mi-
gration and by the chemokinetic, but not chemotactic, activity of
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ReferencesGM-CSF on neutrophils [31]. Therefore, the higher relative
migration of macrophages into GM-CSF-treated peritoneum
would be explained by the secondary release of chemoattractant
molecules with a preferential effect on monocytes/macrophages
(such as C-C chemokines).
In pre-infectious and in overt peritonitis, the peritoneal cellu-
larity and IL-I, IL-6 and IL-8 levels increase greatly [57—62]. In
this sense, the lack of inflammatory mediators (TNFa, IL-i) in the
NPE from GM-CSF-treated patients further suggests that the
GM-CSF-induced response is not a true inflammatory event. The
absence of the pro-inflammatory cytokines might also be favored
by the inhibitory effect on the dialysis solutions on the activation
of the NF-KB transcription factor, since both IL-i and TNFa
expression depend on this transcriptional activity [55]. We have
observed that, unlike IL-i and TNFa, a relationship exists be-
tween the increase in peritoneal macrophages and the IL-6 NPE
levels. The increase in IL-6 may also contribute to the slight
increment in protein losses, because of its effects on vascular wall
permeability [63]. Although mesothelial cells simultaneously re-
lease IL-6 and IL-8 in response to inflammatory stimuli [64—66],
we favor the hypothesis that the IL-6 levels measured are of
macrophage origin, as no increase in IL-8 levels was found in the
GM-CSF-treated patients. Given the capacity of IL-6 to down-
regulate IL-i and TNFa synthesis in macrophages [67—70], GM-
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pro-inflammatory cytokines through IL-6. If this is the case,
GM-CSF would be inducing a primed pre-inflammatory state in
the peritoneum, together with the production of a macrophage
inhibitory factor (IL-6). As a whole, the inhibitory activity of the
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peritoneal situation in which primed macrophages would refrain
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(LPS) were provided. The maintenance of the increased perito-
neal macrophage population in this pre-activated state might
prevent uncontrolled cytotoxic effects, detrimental to the perito-
neal membrane.
Conclusions
Our results confirm the hypothesis that the number and activa-
tion state of peritoneal macrophages may be modulated with
GM-CSF. As no abnormal side-effects were observed, we have
demonstrated for the first time in humans that modulation of the
peritoneal macrophage populations is possible, raising the possi-
bility of using GM-CSF to improve local defensive capabilities in
tissues other than peritoneum. This study also suggests a means of
obtaining large amounts of peritoneal macrophages, necessary for
the analysis of the phenotype, growth and differentiation proper-
ties of human tissue macrophages. Further research is needed to
identify the appropriate dose and interval required for each
individual patient.
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